150 related articles for article (PubMed ID: 2027120)
1. Circulating keratan sulfate: a marker of cartilage proteoglycan catabolism in osteoarthritis.
Thonar EJ; Manicourt DM; Williams J; Lenz ME; Sweet MB; Schnitzer TJ; Otten L; Glant T; Kuettner KE
J Rheumatol Suppl; 1991 Feb; 27():24-6. PubMed ID: 2027120
[TBL] [Abstract][Full Text] [Related]
2. Differential levels of synovial fluid aggrecan aggregate components in experimental osteoarthritis and joint disuse.
Ratcliffe A; Beauvais PJ; Saed-Nejad F
J Orthop Res; 1994 Jul; 12(4):464-73. PubMed ID: 7520485
[TBL] [Abstract][Full Text] [Related]
3. Quantification of keratan sulfate in blood as a marker of cartilage catabolism.
Thonar EJ; Schnitzer TJ; Kuettner KE
J Rheumatol; 1987 May; 14 Spec No():23-4. PubMed ID: 2957502
[TBL] [Abstract][Full Text] [Related]
4. Increased release of matrix components from articular cartilage in experimental canine osteoarthritis.
Ratcliffe A; Billingham ME; Saed-Nejad F; Muir H; Hardingham TE
J Orthop Res; 1992 May; 10(3):350-8. PubMed ID: 1569498
[TBL] [Abstract][Full Text] [Related]
5. Levels of serum keratan sulfate rise rapidly and remain elevated following anterior cruciate ligament transection in the dog.
Manicourt DH; Lenz ME; Thonar EJ
J Rheumatol; 1991 Dec; 18(12):1872-6. PubMed ID: 1724465
[TBL] [Abstract][Full Text] [Related]
6. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions.
Manicourt DH; Altman RD; Williams JM; Devogelaer JP; Druetz-Van Egeren A; Lenz ME; Pietryla D; Thonar EJ
Arthritis Rheum; 1999 Jun; 42(6):1159-67. PubMed ID: 10366108
[TBL] [Abstract][Full Text] [Related]
7. Cartilage proteoglycan changes in experimental canine osteoarthritis.
Adams ME; Grant MD; Ho A
J Rheumatol; 1987 May; 14 Spec No():107-9. PubMed ID: 3625663
[TBL] [Abstract][Full Text] [Related]
8. Serum keratan sulfate concentration as a measure of the catabolism of cartilage proteoglycans.
Thonar EJ
Ryumachi; 1990 Dec; 30(6):461-8. PubMed ID: 2100374
[No Abstract] [Full Text] [Related]
9. The effect of maturation and anterior cruciate ligament transection on the level of keratan sulfate in the serum of dogs.
Cruz TF; Malcolm AJ; Adams ME
J Rheumatol; 1989 Oct; 16(10):1345-50. PubMed ID: 2478708
[TBL] [Abstract][Full Text] [Related]
10. Serum markers of systemic disease processes in osteoarthritis.
Thonar EJ; Masuda K; Lenz ME; Hauselmann HJ; Kuettner KE; Manicourt DH
J Rheumatol Suppl; 1995 Feb; 43():68-70. PubMed ID: 7752142
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous and experimental osteoarthritis in dog: similarities and differences in proteoglycan levels.
Liu W; Burton-Wurster N; Glant TT; Tashman S; Sumner DR; Kamath RV; Lust G; Kimura JH; Cs-Szabo G
J Orthop Res; 2003 Jul; 21(4):730-7. PubMed ID: 12798075
[TBL] [Abstract][Full Text] [Related]
12. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis.
Matyas JR; Atley L; Ionescu M; Eyre DR; Poole AR
Arthritis Rheum; 2004 Feb; 50(2):543-52. PubMed ID: 14872497
[TBL] [Abstract][Full Text] [Related]
13. Lack of association between serum keratan sulfate concentrations and cartilage changes of osteoarthritis after transection of the anterior cruciate ligament in the dog.
Brandt KD; Thonar EJ
Arthritis Rheum; 1989 May; 32(5):647-51. PubMed ID: 2524197
[TBL] [Abstract][Full Text] [Related]
14. Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation.
Bleasel JF; Poole AR; Heinegård D; Saxne T; Holderbaum D; Ionescu M; Jones P; Moskowitz RW
Arthritis Rheum; 1999 Jan; 42(1):39-45. PubMed ID: 9920012
[TBL] [Abstract][Full Text] [Related]
15. Serum keratan sulfate--a marker of predisposition to polyarticular osteoarthritis.
Thonar EJ; Glant T
Clin Biochem; 1992 Jun; 25(3):175-80. PubMed ID: 1633632
[TBL] [Abstract][Full Text] [Related]
16. A pessimistic view of serologic markers for diagnosis and management of osteoarthritis. Biochemical, immunologic and clinicopathologic barriers.
Brandt KD
J Rheumatol Suppl; 1989 Aug; 18():39-42. PubMed ID: 2681766
[TBL] [Abstract][Full Text] [Related]
17. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
Manicourt DH; Poilvache P; Van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867
[TBL] [Abstract][Full Text] [Related]
18. Synovial fluid analyses detect and differentiate proteoglycan metabolism in canine experimental models of osteoarthritis and disuse atrophy.
Ratcliffe A; Beauvais PJ; Saed-Nejad F; Shurety W; Caterson B
Agents Actions Suppl; 1993; 39():63-7. PubMed ID: 8456644
[TBL] [Abstract][Full Text] [Related]
19. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis.
Ishiguro N; Ito T; Ito H; Iwata H; Jugessur H; Ionescu M; Poole AR
Arthritis Rheum; 1999 Jan; 42(1):129-36. PubMed ID: 9920023
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal characterization of synovial fluid biomarkers in the canine meniscectomy model of osteoarthritis.
Lindhorst E; Vail TP; Guilak F; Wang H; Setton LA; Vilim V; Kraus VB
J Orthop Res; 2000 Mar; 18(2):269-80. PubMed ID: 10815829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
